Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Oct;27(4):217-20.
doi: 10.4103/0970-2113.71952.

Multi-drug resistant Acinetobacter ventilator-associated pneumonia

Vishal B Shete  1 , Dnyaneshwari P Ghadage, Vrishali A Muley, Arvind V Bhore
Affiliations

Multi-drug resistant Acinetobacter ventilator-associated pneumonia

Vishal B Shete et al. Lung India. 2010 Oct.

Abstract

Background: Ventilator-associated pneumonia (VAP) due to a multi-drug resistant (MDR) Acinetobacter is one of the most dreadful complications, which occurs in the critical care setting.

Aims and objectives: To find out the incidence of Acinetobacter infection in VAP cases, to determine various risk factors responsible for acquisition of Acinetobacter infection and to determine the antimicrobial susceptibility pattern of Acinetobacter.

Materials and methods: A total of 60 endotracheal aspirate specimens from intubated patients diagnosed clinically and microscopically as VAP were studied bacteriologically. All clinical details and prior exposure to antibiotics were recorded.

Results: An incidence of 11.6% of Acinetobacter VAP cases was recorded. Various underlying conditions like head injury, cerebral hemorrhage and chronic obstructive pulmonary disease (COPD) were found to be associated with Acinetobacter VAP. Acinetobacter strains exhibited MDR pattern.

Conclusion: Strict infection control measures, judicious prescribing of antibiotics, antibiotic resistance surveillance programs and antibiotic cycling should be adopted to control infections due to these bacteria in patients admitted to intensive care units.

Keywords: Acinetobacter; multi-drug resistance; ventilator-associated pneumonia.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Boucher comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clinical Infectious Diseases. 2002;34:1425–30. - PubMed
    1. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-WittelI M, et al. Treatment of multidrug-resistant Acinetobacter baumannii Ventilator-Associated Pneumonia (VAP) with Intravenous Colistin: A comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003;36:1111–8. - PubMed
    1. Baraibar J, Correa H, Mariscal D, Gallego M, Valles J, Rello J. Risk factors for infection by Acinetobacter baumannii in intubated patients with nosocomial pneumonia. Chest. 1997;112:1050–4. - PubMed
    1. Joly-Guillou ML, Wolff M, Pocidalo JJ, Walker F, Carbon C. Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem. Antimicrob Agents Chemother. 1997;41:345–51. - PMC - PubMed
    1. Lortholary O, Fagon JY, Hoi AB, Slama MA, Pierre J, Giral P, et al. Nosocomial acquisition of multiresistant Acinetobacter baumannii: Risk factors and prognosis. Clin Infect Dis. 1995;20:790–6. - PubMed